Clinical Rheumatology

, Volume 32, Issue 10, pp 1451–1458 | Cite as

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from the ATTRA registry

  • Pavel Horák
  • Martina Skácelová
  • Karel Hejduk
  • Andrea Smržová
  • Karel Pavelka
Original Article


The Czech national registry ATTRA collects data from patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis, treated with the biologic drugs. ATTRA is a prospective centralized computerized registry of patients with a focus on efficacy, safety, and quality of life data. Abatacept is approved as a second-line agent which can be prescribed after a failure of at least one TNF-alfa inhibitor. Data of patients treated with abatacept has been collected since 2008. A statistical analysis of the group of RA patients treated with abatacept was performed recently. ATTRA registered 162 patients with RA treated with abatacept, the mean age 51.0 ± 12.2 (median 53.1, 19–74 years), the mean duration of the disease was 14 ± 9.1, median 11.3 years (0–41). One hundred thirty patients (80.2 %) were female. The mean DAS28 was at week 0, 5.9 ± 1.1, at week 16, 4.1 ± 1.4, at week 24, 3.8 ± 1.2, at week 36, 3.6 ± 1.3, and at week 52, 3.5 ± 1.2. DAS28 remission was achieved at week 16 in 15.8 %, at week 24 in 10 %, at week 36 in 20.9 %, and at week 52 in 20.8 % of patients. Of those patients with a DAS28 <2.6 (remission) at week 16, 58.3 % remained in remission at the week 52. Of those patients with DAS28 >5.1 (high disease activity) at the week 16, only 41.7 % had DAS >5.1 at week 52. One year on treatment survival was 82 %. Altogether 50 non-serious adverse events (AE) were reported in 36 patients (22 %) and 11 serious AE in 10 patients (6 %) with the most common being infections (31) and skin rashes (5). Just one non-serious allergic reaction was reported. Data from the ATTRA registry confirms a good overall efficacy and safety profile and a very good on drug survival with abatacept.


Abatacept Registry Rheumatoid arthritis 



The authors would like to acknowledge all cooperating centers of ATTRA registry: Prof. Karel Pavelka, Institute of Rheumatology in Prague; Marie Sedláčková, MD, Department of Rheumatology, Thomayer Faculty Hospital in Prague; Hana Brabcová, MD, Department of Rheumatology, Faculty Hospital in Plzeň; Prof. Pavel Horák, III, Department of Internal Medicine-Nephrology, Rheumatology, Endocrinology, Palacky University of Olomouc; Ladislav Bortlík, MD, ARTROSCAN, Ostrava; Associate Prof. Petr Bradna, II, Department of Internal Medicine, Faculty Hospital in Hradec Králové; Ivana Součková, MD, Department of Rheumatology, Regional Hospital in Liberec; Zdeněk Fojtík, MD, Department of Rheumatology, Faculty Hospital of Brno; Sevda Augustinová, MD, Medipoint PLUS, České Budějovice; Petr Vítek, MD, PV—Medical, Zlín; Alena Tichá, MD, Rheumatology Clinic Sokolov; Dagmar Galatíková, MD, Rheumatology Clinic Bruntál; Helena Šedivá, MD, Rheumatology Clinic, Ústí nad Labem; Olga Janušková, MD, Rheumatology Clinic, Kroměříž; Eva Dokoupilová, MD, Rheumatology Clinic, Uherské Hradiště; Associate Prof. Petr Němec, Internal Department Rheumatology Clinic, Faculty Hospital Svatá Anna, Brno; Vlastimil Novotný, MD, Rheumatology Clinic, Mariánské Lázně ; Julius Vachtenheim, MD, Rheumatology Clinic Jihlava; Pavla Vavřincová, MD, Rheumatology Clinic, Faculty Hospital Motol, Prague; Klára Šírová, MD, Rheumatology Clinic, Ostrava; Vít Kuba, MD, Rheumatology Clinic Chomutov; Associate Prof. Josef Hoza, Children Hospital Faculty Hospital in Prague; Iva Kielkowská, MD, Faculty Hospital, Ostrava; Zdeněk Dvořák, MD, ARTHROMED, Pardubice; Marie Macků, MD, Children Department , Faculty Hospital, Brno; Jana Korbielová, MD, REDIAMB Havířov; Libor Novosad, MD, L.K.N. Arthrocentrum, Hlučín; Jana Kopačková, MD, ARTMEDI UPD, Hostivice. This study was funded by ATTRA registry, Czech Republic




  1. 1.
    Kremer JM, Westhovens R, Leon M et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907–1915PubMedCrossRefGoogle Scholar
  2. 2.
    Linsley PS, Brady W, Urnes M et al (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561–569PubMedCrossRefGoogle Scholar
  3. 3.
    Tegzová D, Vencovsky J, Dusek L, Pavelka K (2004) Clinical register of TNF alpha blocking therapy of Czech rheumatologic society. Project ATTRA. Results of study: clinical efficacy and safety. Ann Rheum Dis 63(Suppl 1):263Google Scholar
  4. 4.
    Prevoo MLL, van ‘t Hof MA, Kuper HH et al (1995) Modified disease activity scores that includes twenty eight- joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRefGoogle Scholar
  5. 5.
    Van Gestel AM, Prevoo MLL, van ‘t Hof MA (1996) Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 39:34–40PubMedCrossRefGoogle Scholar
  6. 6.
    Prevoo MLL, van Gestel AM, van ‘t Hof MA et al (1996) Remission in a prospective study of patients with rheumatoid arthritis. Br J Rheumatol 35:1101–1105PubMedCrossRefGoogle Scholar
  7. 7.
    The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefGoogle Scholar
  8. 8.
    Jenkinson C, Coulter A, Wright L (1993) Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 306:1437–1440PubMedCrossRefGoogle Scholar
  9. 9.
    Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346–1353PubMedCrossRefGoogle Scholar
  10. 10.
    Kremer JM, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:2263–2271PubMedCrossRefGoogle Scholar
  11. 11.
    Kremer JM, Genant H, Moreland L et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865–876, 2006PubMedCrossRefGoogle Scholar
  12. 12.
    Burmester GR (2012) Remission. Nat Rev Rheumatol. doi: 10.1038/nrrheum.2011.201 [Epub ahead of print]Google Scholar
  13. 13.
    Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor in inhibition. N Engl J Med 353:1114–1123PubMedCrossRefGoogle Scholar
  14. 14.
    Genovese MC, Schiff M, Luggen M et al (2006) Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Arthritis Rheum 54(Suppl 9):247Google Scholar
  15. 15.
    Dougados M, Schmidely N, Le Bars M et al (2009) Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 68:484–489PubMedCrossRefGoogle Scholar
  16. 16.
    Westhovens R, Luggen M, Russell A et al (2008) Abatacept provides durable improvements in RA disease status and a consistent safety profile through 3 years in the aim and attain trials. Rheumatology 47(Suppl 2):46Google Scholar
  17. 17.
    Emery P, Kremer JM, Moreland R et al (2008) Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate. Rheumatology 47(Suppl 2):48Google Scholar
  18. 18.
    Kremer JM, Russell AS, Emery P et al (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 70:1826–1830PubMedCrossRefGoogle Scholar
  19. 19.
    Schiff M, Bessette L (2010) Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clin Rheum 29:583–589CrossRefGoogle Scholar
  20. 20.
    Vital EM, Emery P (2006) Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2:365–375PubMedCrossRefGoogle Scholar
  21. 21.
    Russel AS, Wallenstein GV, Li T et al (2007) Abatacept Improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 66:189–194CrossRefGoogle Scholar
  22. 22.
    Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32PubMedCrossRefGoogle Scholar
  23. 23.
    van Riel PL, van de Laar MA Evaluation and monitoring of biologicals in the treatment of rheumatoid arthritis in daily clinical practive. DREAM, Report Winter 2011/2012, Feb 2012, 1–39, unpublished dataGoogle Scholar
  24. 24.
    Lindblad S, Stawiarz L, Swedish Rheumatology Quality Registry (2012) Gender and prevoius treatment influence outcomes from abatacept in a 5 years cohort of rheumatoid arthritis. Ann Rheum Dis 71(Suppl 3):383, AbstractGoogle Scholar
  25. 25.
    Leffers HC, Osterggard M, Glintborg B et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70:1216–1222PubMedCrossRefGoogle Scholar
  26. 26.
    Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103PubMedCrossRefGoogle Scholar
  27. 27.
    Schiff M, Keiserman M, Codding C et al (2006) The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum 54(Suppl 1):43Google Scholar
  28. 28.
    Schiff M, Pritchard C, Teng J et al (2007) The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: results from the ARRIVE trial. Ann Rheum Dis 66(Suppl 2):89Google Scholar
  29. 29.
    Smitten A, Simon R, Qi K et al (2008) Hospitalized infections in the abatacept RA clinical development program: an epidemiological assessment with >10,000 person-years of exposure. Arthritis Rheum 58(Suppl 9):786–787Google Scholar
  30. 30.
    Weinblatt M, Combe B, Covucci A et al (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54:2807–2816PubMedCrossRefGoogle Scholar
  31. 31.
    WHO (1969) The evaluation of drugs: whose responsibility? IOMS Round Table Conference, October 1968. WHO Chron 23:256–263Google Scholar
  32. 32.
    Singh JA, Wells GA, Christenses R et al. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16;2:CD008794Google Scholar
  33. 33.
    Gottenberg JE, Ravaud P, Bardin T et al (2010) Prospective follow-up of abatacept treatment in 920 patients with refractory rheumatoid arthritis: tolerance and efficacy data from French ORA (Orencia and rheumatoid arthritis) registry. Ann Rheum Dis 69(Suppl 3):386Google Scholar
  34. 34.
    Weinblatt ME, Schiff M, Valente R et al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Arthritis Rheum 65:28–38PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • Pavel Horák
    • 1
  • Martina Skácelová
    • 1
  • Karel Hejduk
    • 2
  • Andrea Smržová
    • 1
  • Karel Pavelka
    • 3
  1. 1.Department of Internal Medicine III—Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and DentistryPalacký University in Olomouc, University Hospital OlomoucOlomoucCzech Republic
  2. 2.Institute of Biostatistics and AnalysesMasaryk UniversityBrnoCzech Republic
  3. 3.Institute of Rheumatology, 1st Medical FacultyCharles University in PraguePragueCzech Republic

Personalised recommendations